ACM
SMMT icon

ADAR1 Capital Management’s Summit Therapeutics SMMT Stock Holding History

ADAR1 Capital Management’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-100,000
Closed -$2.13M – 256
2025
Q2 		$2.13M Hold
100,000
– – 0.33% 53
2025
Q1 		$1.93M Buy
+100,000
New +$2.01M 0.36% 60

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

ADAR1 Capital Management's SMMT Position: Q2 2026 in Review

ADAR1 Capital Management increased its Summit Therapeutics (SMMT) stake by 109% in Q2 2026, buying an estimated $1.77M and bringing the position to 191,869 shares worth $2.8M. The position accounts for 0.13% of the portfolio, ranked #130.

ADAR1 Capital Management first reported a position in SMMT in Q2 2025 and has held it in 5 quarters since. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • ADAR1 Capital Management held 191,869 shares of Summit Therapeutics worth $2.8M as of Q2 2026.
  • ADAR1 Capital Management bought 100,000 Summit Therapeutics shares in Q2 2026, an estimated $1.77M.
  • Summit Therapeutics made up 0.13% of ADAR1 Capital Management's portfolio in Q2 2026, its #130 holding.
  • ADAR1 Capital Management first reported a position in Summit Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.